Core Insights - Takeda Pharmaceutical Company Limited (NYSE:TAK) is identified as one of the best healthcare stocks to buy for 2026, despite facing challenges due to VYVANSE's loss of exclusivity [1][2] Financial Performance - For Q3 FY2025, Takeda reported a revenue of ¥3,411.2 billion, reflecting a year-over-year decline of 3.3% at constant exchange rates [2] - Core operating profit decreased by 3.4% to ¥971.6 billion, while reported operating profit increased by 1.2% to ¥422.4 billion [2] - Operating cash flow rose by 15.8% to ¥966.9 billion, and adjusted free cash flow increased by 10.1% to ¥625.9 billion, indicating strong cash flow management [2] Product Performance - Growth and launch products contributed positively, rising by 6.7% at constant exchange rates and now accounting for 52% of total revenue [1] - Key growth drivers included Entyvio (+7.4%), Livtencity (+43.6%), and Qdenga (+22.1%), which helped mitigate the impact of VYVANSE's significant decline of 45.7% [1] Upcoming Products - The company is preparing to launch three transformative medicines—Oveporexton, Rusfertide, and Zasocitinib—between late 2026 and early 2027, aiming to drive long-term growth [2] - Takeda is also accelerating late-stage programs in gastrointestinal, neuroscience, and oncology sectors [2] New Product Launch - On January 22, Takeda announced the U.S. launch of GAMMAGARD LIQUID ERC, an immunoglobulin therapy for primary immunodeficiency patients aged two and older, which can be administered without reconstitution [3] - The product features Enhanced Removal Capability to lower IgA levels and is available in various vial sizes, enhancing treatment options for patients [3] Company Overview - Takeda is a top-20 global, R&D-driven biopharmaceutical company headquartered in Japan, focusing on innovative medicines in oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines [4]

Core Insights - Takeda Pharmaceutical revised its full-year revenue guidance downward to JPY 4.53 trillion, reflecting a low single-digit decline at constant exchange rates due to stronger-than-anticipated erosion of Vyvanse generics in the U.S. [1][7] - The company maintained its full-year guidance for core operating profit at JPY 1.15 trillion and core EPS at JPY 486, supported by disciplined cost management [1][7] - Takeda reported adjusted free cash flow of JPY 625.9 billion for the period, indicating strong cash generation despite a $1.2 billion upfront payment to Innovent Biologics [2][7] Financial Performance - For the nine-month period, Takeda's revenue was just over JPY 3.4 trillion, down 3.3% year over year (down 2.8% at constant exchange rates) [3] - Core operating profit decreased by 3.4% year over year to JPY 971.6 billion, while reported operating profit rose by 1.2% to JPY 422.4 billion [3] - Core EPS was reported at JPY 428, with reported EPS at JPY 137 [3] Growth Drivers - Growth-and-launch products accounted for over 50% of total revenue, growing 6.7% year to date, driven by Entyvio and vaccines [5][8] - Entyvio experienced a growth of 7.4% at constant exchange rates, attributed to strong third-quarter performance and formulary wins [9] - Qdenga vaccine growth accelerated to 22.1%, primarily driven by demand in Brazil [10] Pipeline Developments - Takeda is preparing for several late-stage product launches, with three key pipeline assets—oveporexton, rusfertide, and zasocitinib—expected to shape future growth [4][11] - Positive phase III readouts for oveporexton and rusfertide have led to NDA filings, with launches planned within the current calendar year [6][11] - Zasocitinib showed significant efficacy in psoriasis treatment, with a summer submission target and a potential launch in 2027 [14] Leadership Transition - CEO Christophe Weber announced his transition from the main presenter role, with Julie Kim set to take over leadership in June [17]